Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.

ABSTRACT:

Background

We previously reported the initial results of the first multicenter, randomized, double-blind, placebo-controlled clinical trial of peanut sublingual immunotherapy (SLIT), observing a favorable safety profile associated with modest clinical and immunologic effects in the first year.

Objective

We sought to provide long-term (3-year) clinical and immunologic outcomes for our peanut SLIT trial. Key end points were (1) percentage of responders at 2 years (ie, could consume 5 g of peanut powder or a 10-fold increase from baseline), (2) percentage reaching desensitization at 3 years, (3) percentage attaining sustained unresponsiveness after 3 years, (4) immunologic end points, and (5) assessment of safety parameters.

Methods

Response to treatment was evaluated in

SUBMITTER: Burks AW 

PROVIDER: S-EPMC4527157 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature